Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

@inproceedings{Solomkin2015CeftolozaneTazobactamPM,
  title={Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)},
  author={Joseph Solomkin and Ellie Hershberger and Benjamin Miller and Myra W. Popejoy and Ian Friedland and Judith N. Steenbergen and Minjung Yoon and Sylva H Collins and Guojun Yuan and Philip S. Barie and Christian Eckmann},
  booktitle={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2015}
}
BACKGROUND Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. METHODS ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 24 times over the past 90 days. VIEW TWEETS
60 Extracted Citations
39 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 60 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 39 references

and Drug Administration

  • US Foo
  • Guidance for industry. Antibacterial therapies…
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…